T. Rowe Price Associates’s FibroGen FGEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $61K | Sell |
|
|||||
|
2024
Q3 | $63K | Buy |
|
|||||
|
2024
Q2 | $83K | Sell |
|
|||||
|
2024
Q1 | $276K | Buy |
|
|||||
|
2023
Q4 | $99K | Buy |
|
|||||
|
2023
Q3 | $62K | Buy |
|
|||||
|
2023
Q2 | $126K | Sell |
|
|||||
|
2023
Q1 | $15.1M | Sell |
|
|||||
|
2022
Q4 | $14.9M | Buy |
|
|||||
|
2022
Q3 | $433K | Buy |
|
|||||
|
2022
Q2 | $215K | Buy |
|
|||||
|
2022
Q1 | $209K | Buy |
|
|||||
|
2021
Q4 | $186K | Sell |
|
|||||
|
2021
Q3 | $323K | Sell |
|
|||||
|
2021
Q2 | $13.2M | Sell |
|
|||||
|
2021
Q1 | $65.9M | Sell |
|
|||||
|
2020
Q4 | $135M | Sell |
|
|||||
|
2020
Q3 | $158M | Sell |
|
|||||
|
2020
Q2 | $167M | Buy |
|
|||||
|
2020
Q1 | $71.3M | Sell |
|
|||||
|
2019
Q4 | $100M | Sell |
|
|||||
|
2019
Q3 | $91.9M | Buy |
|
|||||
|
2019
Q2 | $112M | Sell |
|
|||||
|
2019
Q1 | $138M | Buy |
|
|||||
|
2018
Q4 | $105M | Sell |
|
|||||
|
2018
Q3 | $142M | Sell |
|
|||||
|
2018
Q2 | $148M | Buy |
|
|||||
|
2018
Q1 | $90.1M | Buy |
|
|||||
|
2017
Q4 | $76.4M | Buy |
|
|||||
|
2017
Q3 | $72.8M | Buy |
|
|||||
|
2017
Q2 | $26M | Sell |
|
|||||
|
2017
Q1 | $20M | Sell |
|
|||||
|
2016
Q4 | $18.2M | Sell |
|
|||||
|
2016
Q3 | $18.7M | Sell |
|
|||||
|
2016
Q2 | $15.2M | Sell |
|
|||||
|
2016
Q1 | $19.7M | Sell |
|
|||||
|
2015
Q4 | $28.3M | Buy |
|
|||||
|
2015
Q3 | $20.3M | Sell |
|
|||||
|
2015
Q2 | $21.9M | Sell |
|
|||||
|
2015
Q1 | $30.3M | Sell |
|
|||||
|
2014
Q4 | $26.4M | Buy |
|